PolarityTE, Inc. (PTE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.6100-0.0100 (-0.62%)

As of 10:33AM EDT. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	1.6200
Open	1.6000
Bid	1.6000 x 2900
Ask	1.6100 x 1800
Day's Range	1.5900 - 1.6500
52 Week Range	0.7800 - 5.6200
Volume	88,054
Avg. Volume	1,450,848

Market Cap	61.926M
Beta (5Y Monthly)	1.74
PE Ratio (TTM)	N/A
EPS (TTM)	-2.8740
Earnings Date	Aug 06, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Jan 12, 2016
1y Target Est	3.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors
PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors. Dr. Shen brings extensive clinical development, medical, health economics, regulatory, and quality control experience to PolarityTE’s Board of Directors. Dr. Shen spent more than 15 years at Johnson & Johnson, where she was most recently Vice President of Clinical Development and Regulatory Affairs of the Global Surgery Group. Dr. Shen joined Royal Philips over five years ago and currently serves as Senior Vice President, Head of Global Regulatory, Medical, Clinical & Health Economic Outcomes Research (HEOR) Affairs and Global Government Regulations & Standards. In her current role, Dr. Shen provides strategic direction and oversight for all clinical and regulatory functions, globally supporting three business sectors in 140 countries and 500 employees.
- Legend Biotech Announces Chief Executive Officer Transition
  Business Wire
- VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer
  Business Wire
Business Wire
PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m. Eastern Time.
Business Wire
PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE™ Diabetic Foot Ulcer Trial
PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care (SOC) vs SOC alone (NCT03881254). 50 patients were evaluated across 13 sites with 25 patients receiving SkinTE plus SOC and 25 patients receiving only SOC.